Machine Learning Enhances Diagnosis and Monitoring of Colorectal Cancer
A novel machine learning platform developed by researchers enhances the diagnosis and monitoring of colorectal cancer through metabolic biomarker analysis, offering a promising noninvasive approach to early detection and disease progression assessment.
Researchers have developed an innovative machine learning platform aimed at improving the diagnosis and monitoring of colorectal cancer. This advanced tool analyzes metabolic differences in biological samples from over 1,000 individuals, distinguishing between patients with colorectal cancer and healthy controls. The study identified specific metabolic shifts that correlate with disease severity and genetic risk factors, offering promising avenues for noninvasive diagnostics.
The platform, named PANDA (PLS-ANN-DA), integrates partial least squares-discriminant analysis (PLS-DA) and artificial neural networks (ANN) to enhance predictive accuracy. Using blood samples from large-scale research initiatives, the team examined metabolites—products of biochemical reactions—and transcriptomic data, providing a comprehensive view of molecular alterations associated with cancer.
Although not intended to replace colonoscopy, the current gold standard for screening, this biomarker discovery pipeline could significantly aid early detection and disease progression monitoring. Its potential also extends to assessing treatment responses more rapidly than traditional methods, such as pathology or protein markers.
The researchers emphasize that further validation with additional samples is necessary before clinical application. This approach also offers insights into cancer biology, especially pathways involving purines, which are crucial for DNA synthesis and repair. The study demonstrates a robust advancement in machine learning and bioinformatics, opening pathways for future diagnostic technologies in colorectal cancer management.
This groundbreaking work was published in iMetaOmics, with contributions from researchers at Ohio State University and the City of Hope National Cancer Center. Additional insights from this study could revolutionize how clinicians diagnose, monitor, and understand colorectal cancer in the future.
Source: https://medicalxpress.com/news/2025-05-machine-tool-colorectal-cancer.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Choosing the Correct Blood Pressure Monitor for Accurate Home Readings
Learn how to select the correct blood pressure cuff size and device validation to ensure accurate readings for effective hypertension management at home.
Using Blood Markers GDF-15 and eGFRdiff to Predict Kidney Disease Progression in Diabetes
New research identifies blood biomarkers GDF-15 and eGFRdiff as independent predictors of kidney decline and mortality in diabetes, offering improved risk assessment and early intervention opportunities.
Potential Anti-Cancer Benefits of GLP-1 Receptor Agonists Beyond Weight Loss
New research indicates that GLP-1 receptor agonists, used for diabetes and weight loss, may also provide significant protection against obesity-related cancers beyond their metabolic effects. The study compares these medications to bariatric surgery, revealing potential anti-cancer benefits that merit further investigation.
Enhancing Physician Awareness and Screening for Fragile X-Related Conditions
Experts from UC Davis emphasize the urgent need to improve awareness and screening of fragile X-related genetic conditions, including fragile X syndrome and associated disorders, to enable early diagnosis and intervention.